| Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial. |
|
|
| J Clin Oncol 41 (suppl 4, abstr 694) |
Abstract |
2023 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2023.41.4_suppl.694 |
|
|
| https://doi.org/10.1016/j.annonc.2023.09.2473 |
|
|
| 2023 |
|
2023 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2023.09.2573 |
|
|
| Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study. |
|
|
| Ann Oncol 34 (Supplement 2, S899, 1623P) |
|
2023 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2023.09.2572 |
|
|
| Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group. |
|
|
| Ann Oncol 34 (1): 91-100 |
|
2023 |
|
Pankreaskarzinom
|
|
|
| www.annalsofoncology.org/article/S0923-7534(22)04184-9/fulltext |
|
|
| Predictive Value of Computed Tomography on Surgical Resectability in Locally Advanced Pancreatic Cancer treated with Multiagent Induction Chemotherapy: Results from a prospective, multicentre Phase 2 Trial (NEOLAP-AIO-PAK-0113). |
|
|
| Eur J Radiol (168) |
|
2023 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.ejrad.2023.110834 |
|
|
| Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial. |
|
|
| J Clin Oncol 41 (16_suppl): 4026 |
|
2023 |
|
Ösophagus-/Magenkarzinome
|
|
|
| doi.org/10.1200/JCO.2023.41.16_suppl.4026 |
|
|
| Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH). |
|
|
| Ann Oncol 34 (Supplement 2, S1017, 1890P) |
|
2023 |
|
Nierenzellkarzinom
|
|
|
| doi.org/10.1016/j.annonc.2023.09.1120 |
|
|
| Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass). |
|
|
| Eur Urol 84 (6): 571-8 |
|
2023 |
|
Nierenzellkarzinom
|
|
|
| doi.org/10.1016/j.eururo.2023.09.004 |
|
|
| Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. |
|
|
| Lancet Oncol 24 (11): 1252-65 |
|
2023 |
|
Nierenzellkarzinom
|
|
|
| doi.org/10.1016/S1470-2045(23)00449-7 |
|
|
| Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC) - subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH). |
|
|
| Urologie 62 (Suppl. 2) |
|
2023 |
|
Nierenzellkarzinom
|
|
|
| doi.org/10.1007/s00120-023-02165-7 |
|
|
